Article
Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia.
Pharmacogenomics - 1 Apr 2011
Bitsios Panos, Roussos Panos
Abstract excerpt
It is widely accepted that abnormal prefrontal cortex biology resulting in deficient cognition is a primary problem in schizophrenia and that all currently available antipsychotics fail to improve cognitive and negative symptoms originating from this deficit. Evidence from basic science has revealed the importance of prefrontal dopamine signaling for optimal prefrontal function. This article describes succinctly...
Topics
Join the communities discussing this publication.